{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:41:11Z","timestamp":1737632471516,"version":"3.33.0"},"posted":{"date-parts":[[2024,10,14]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,6]]},"abstract":"<title>Abstract<\/title>\n        <p>Parkinson\u2019s disease (PD) is the second most prevalent neurodegenerative disorder. However, current treatments are directed at symptoms and lack ability to slow or prevent disease progression. Large-scale genome-wide association studies (GWAS) have identified numerous genomic loci associated with PD, which may guide the development of disease-modifying treatments. We presented a systems genetics approach to identify potential risk genes and repurposable drugs for PD. First, we leveraged non-coding GWAS loci effects on multiple human brain-specific quantitative trait loci (xQTLs) under the protein-protein interactome (PPI) network. We then prioritized a set of PD likely risk genes (pdRGs) by integrating five types of molecular xQTLs: expression (eQTLs), protein (pQTLs), splicing (sQTLs), methylation (meQTLs), and histone acetylation (haQTLs). We also integrated network proximity-based drug repurposing and patient electronic health record (EHR) data observations to propose potential drug candidates for PD treatments. We identified 175 pdRGs from QTL-regulated GWAS findings, such as <italic>SNCA<\/italic>, <italic>CTSB<\/italic>, <italic>LRRK2, DGKQ<\/italic>, <italic>CD38 <\/italic>and <italic>CD44<\/italic>. Multi-omics data validation revealed that the identified pdRGs are likely to be druggable targets, differentially expressed in multiple cell types and impact both the parkin ubiquitin-proteasome and alpha-synuclein (a-syn) pathways. Based on the network proximity-based drug repurposing followed by EHR data validation, we identified usage of simvastatin as being significantly associated with reduced incidence of PD (fall outcome: hazard ratio (HR) = 0.91, 95% confidence interval (CI): 0.87\u20130.94; for dementia outcome: HR = 0.88, 95% CI: 0.86-0.89), after adjusting for 267 covariates. Our network-based systems genetics framework identifies potential risk genes and repurposable drugs for PD and other neurodegenerative diseases if broadly applied.<\/p>","DOI":"10.21203\/rs.3.rs-4869009\/v1","type":"posted-content","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T10:19:10Z","timestamp":1728901150000},"source":"Crossref","is-referenced-by-count":0,"title":["A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson\u2019s disease"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1736-2847","authenticated-orcid":false,"given":"Feixiong","family":"Cheng","sequence":"first","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Dou","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Cornell University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jielin","family":"Xu","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pieper","sequence":"additional","affiliation":[{"name":"Case Western Reserve University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Case Western Reserve University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Leverenz","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-9461","authenticated-orcid":false,"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[{"name":"University of Nevada, Las Vegas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4869009\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4869009\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:07:53Z","timestamp":1737533273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4869009\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4869009\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41531-025-00870-y","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,10,14]]},"subtype":"preprint"}}